cSCC Patient Clinic

Program Overview

Available treatment options for cutaneous squamous cell carcinoma (cSCC) are expanding and involving more interdisciplinary dialogue. This slides/audio presentation features 3 clinical case scenarios with feedback and commentary by a medical oncologist, surgeon, and dermatologist exploring topics in immunotherapy, Mohs surgery, and complex patient presentations.

Credit Expired

CE Credit Expired

Target Audience

The intended audience for this activity is Mohs surgeons, medical oncologists, and dermatologists who manage patients with cutaneous squamous cell carcinoma (cSCC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Utilize novel and emerging agents to manage advanced cutaneous squamous cell carcinoma (cSCC) based on their efficacy and safety data and mechanisms of action
Identify patients with cSCC who are unlikely to be cured by surgery to expedite appropriate workup, multidisciplinary team collaboration, and referral for systemic therapy (including, immunotherapy) to improve patient outcomes and quality of life
Incorporate shared decision making (SDM), quality of life assessment and management, and collaborative care for patients with cSCC to improve patient outcomes

Activity Faculty

Chrysalyne D. Schmults, MD, MSCE (Chair)

Associate Professor, Dermatology
Harvard Medical School
Director, Mohs and Dermatologic Surgery Center
Dana-Farber/Brigham and Women’s Cancer Center
Boston, MA

Omid Hamid, MD

Chief, Translational Research and Immunotherapy
Director, Cutaneous Oncology
The Angeles Clinic and Research Institute
Los Angeles, CA

Anokhi Jambusaria, MD, MSCE, FAAD

Assistant Professor, Division of Dermatology
Department of Internal Medicine
The University of Texas
Austin Dell Medical School
Austin, TX

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Featured RMEI CE Activities

cSCC Patient Clinic

Program Overview

Target Audience

Educational Objectives

Activity Faculty

Chrysalyne D. Schmults, MD, MSCE (Chair)

Omid Hamid, MD

Anokhi Jambusaria, MD, MSCE, FAAD

Overcoming Obstacles to Optimal Multiple Sclerosis (MS) Care in Minority Patient Populations

Collaboration Nation: Interprofessional Perspectives on Immunotherapy and Team-Based Care for Non-Melanoma Skin Cancer

Spinal Muscular Atrophy: An Interprofessional Approach

Tackling the Problem Head On: Key Considerations for CMV in the Post-Transplant Setting: A Care Team Forum®

Subscribe